Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009

Size: px
Start display at page:

Download "Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009"

Transcription

1 Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009

2 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations SLL 8% MCL 6% MZL, MALT 8% FL 22% MZL 3% others 6% DLBCL 35% anaplastic T/null 2% PTCL 7% lymphoblastic 2% Burkitt 1%

3 Increasing of the rates of NHL, including DLBCL, in the US by 3-4% each year from 1973 to the mid-1990s

4 DLBCL in the WHO classification: heterogeneous group of diseases WHO Classification, IARC Press: Lyon 2008

5 Distinct types of DLBCL identified by gene expression profiling 2 major patterns of gene expression which are clinically distinct Alizadeh AA et al. Nature 2000;403:503

6 International Prognostic Index Unfavorable variables Age > 60 years Poor performance status (ECOG 2) Advanced Ann Arbor stage (III-IV) Extranodal involvement 2 sites High serum LDH (>normal) Risk group Unfavourable variables All patients Patients 60 Low 0 or 1 0 Low/intermediate 2 1 High/intermediate 3 2 High 4 or 5 3 Shipp M. N Engl J Med 329:987,1993

7 Blood 2007;109: PFS IPI and R-IPI for patients treated with R-CHOP OS

8 Treatment of DLBCL

9 CHOP versus second generation regimens

10 HOWEVER! Improvement possible with dose-dense, dose-intense or HDT regimens Salles G, Ed. Program, EHA 2008

11

12

13 MInT trial design CD20+ DLBCL years IPI 0, 1 stages II-IV I with bulk * CHOP-21 (n=396) CHOEP-21 (n=362) MACOP-B (n=33) PMitCEBO (n=32) Randomization 6 x CHOP-like* Gy (Bulk, E) 6 x CHOP-like* + rituximab Gy (Bulk, E) Pfreundschuh M et al. Lancet Oncol 2006;7:379

14 MInT trial EFS PFS OS Pfreundschuh M et al. Lancet Oncol 2006

15 RECOVER trial 6 x CHOP Gy (Bulk, E) CD20+ stages I-IV years random 2 x 2 factorial design 8 x CHOP Gy (Bulk, E) 6 x CHOP Gy (Bulk, E) + 8 x rituximab Pfreundschuh M et al. Lancet Oncol x CHOP Gy (Bulk, E) + 8 x rituximab

16 Superiority of R-CHOP: constistency of all studies Pfreudschuh M, Lancet Oncol 2008 ECOG British Columbia Habermann T, JCO 2006 Sehn LH, JCO 2005

17 Q1: Which place for dose-dense regimens in the area of rituximab? The «story» of CHOP14 Superiority of CHOP14 over CHOP21 Pfreundschuh M et al. Blood 2004 Superiority of R-CHOP21 over CHOP21 MInT trial Pfreundschuh M et al. Lancet Oncol 2006 Superiority of R-CHOP14 over CHOP14 RECOVER trial Pfreundschuh M et al. Lancet Oncol 2008 No proof today that R-CHOP14 is superior to R-CHOP21!

18 GELA LNH 03-6B yrs, aa-ipi = 1, 2 or 3 4 IT MTX Closed 12/ pts included R-CHOP 21 R Wks Prophylactic Darbepoietin alfa Interventional Darbepoietin alfa Wks R-CHOP 14 4 IT MTX UK Clinical Research Network: R-CHOP14 vs. R-CHOP21 DLBCL > 18 years

19 Q2: Which place for dose-intense regimens in the area of rituximab? GELA LNH 03-2B < 60 yrs, aa-ipi = 1 R-ACVBP 14 MTX IFM - VP16 ARA-C R Wks 4 IT MTX Wks R-CHOP 21 Closed 12/ pts included

20 CALGB/NCI trial Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Primary outcome: 5-y EFS Secondary outcome: molecular predictors as measured by cdna microarray 5 years after completion of study treatment No proof today that dose-intense regimens are superior to R-CHOP in the area of rituximab!

21 Q3: Role of PET in the management of DLBCL? PR according the IWC CR according the IWC+PET No evidence of disease after 29.5 mths Juweid ME et al. JCO 2007;23:4652

22 Revised response criteria for malignant lymphoma Cheson BD et al. JCO 2007;25:579

23 Early PET evaluation in DLBCL? Haioun C et al. Blood 2005;106:1376

24 Primary objective To evaluate if an early positive PET after 2 cycles of R-CHOP-14 can be used to identify a group of patients having a poor prognosis. Primary endpoint Event-free survival at 2 years

25 GELA LNH 07-3B study

26 Q4: How to further improve the results of R-CHOP? Optimize use of rituximab? Dose Schedule of administration Maintenance Add something to R-CHOP? RIT? Other agent? Maintenance treatment? New molecules?

27 Dose-Dense rituximab in elderly patients with poor-prognosis DLBCL The Dense-R-CHOP14 trial Pfreundschuh M et al. ASH 2007, abstr. 789

28 Rituximab pharmacokinetics Serum Levels Pfreundschuh M et al. ASH 2007, abstr. 789

29 Dense-R-CHOP14 (n=47) Vs. R-CHOP14 (n=306) Pfreundschuh M et al. ASH 2007, abstr. 789

30 RIT in DLBCL 90Y-ibritumomab tiuxetan: interesting efficacy if no prior rituximab but of limited value as a single agent in patients previously treated with R-chemo Morschhauser F et al. Blood 2007 Role for RIT instead of radiotherapy in localized disease? Role of RIT in consolidation after chemo-immunottt?

31 Studies combining chemotherapy and RIT for untreated DLBCL Patients Study SWOG Phase II Stage II bulky, III-IV R-CHOP x 6 Bexxar SWOG Phase II Early stage Unfav.,no bulk CHOP x 3 IFXRT Zevalin ZEAL Phase III > 60 years R-CHOP x 6 If CR/uCR Zevalin vs. Obs. MSKCC/NCI Phase II > 60 years IPI 2 R-CHOP x 6 Zevalin

32 Avastin in combination with R-CHOP (RA-CHOP) in patients with DLBCL 4 x R-CHOP21 + placebo 4 x R-CHOP21 + placebo 3 x R-CHOP14 + placebo R 4 x R-CHOP21 + Avastin (15mg/kg/3w) or 3 x R-CHOP14 + Avastin (10mg/kg/2w) PR MR CR or 3 x R-CHOP14 + 2R + placebo CR PR MR 4 x R-CHOP21 + Avastin (15mg/kg/3w) or 3 x R-CHOP14 + 2R + Avastin (10mg/kg/2w) Interim staging or Interim staging CR CR Observation Avastin (15mg/kg/3w) up to 1 y

33 Bortezomib combined with R-CHOP - a randomized phase 2 trial - 49 pts included 40/48 pts: CR/CRu (15/16 DLBCL) Grade 3/4 neurotoxicity in 10 pts N. Mounier et al., Lugano 2008

34 REMARC - RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID ) MAINTENANCE IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE

35 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large BCell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With FirstLine Rituximab-Chemotherapy (PILLAR-2) Stage III-IV, or stage II bulky Poor risk patients (IPI 3) 18 years In CR after R-CHOP

36 New molecules New monoclonal antibodies Same antigen (ofatumumab, GA-101 ) Different antigens: CD19, CD22, CD40, CD80 Bispecific Histone deacetylase inhibitors SAHA (vorinostat) MGCD0103 (Younes A, ASH 2007) SYK inhibitors (Young RM, Blood 2009) ABT-263 (Ackler S, Mol Cancer Ther 2008) Enzastaurin (Robertson MJ, JCO 2007) Pralatrexate (O Connor OA, BJH 2007)

37 Thank you!

38 Q5: Which treatment for localized low-risk DLBCL? Miller et al. NEJM 1998;339:21 Superiority of 3 CHOP + RXT compared to CHOP alone BUT: Med. f-up 44 months 50% patients > 60 years 14% «drop out» in chemo arm 20% patients with LDH > N Only 75% DLBCL Updated results (med. f-up 8.2 years) Miller et al. ASH 2001: abstr No more superiority of combined CT+RXT (cross-over of the curves) excess of the number of deaths due to lymphoma after 5 years in the CT-RT arm

39 Reyes F et al. NEJM 2005;352: Med. F-up 7.7 years 5-y EFS : 82% vs. 74% 5-y OS : 90% vs. 81% Independent benefit according to stage (I/II) and to tumor burden (+/- bulk)

40 MINT TRIAL Pfreundschuh et al., Lancet Oncol 2006;7:379

41 FLYER TRIAL years, IPI=0, no bulk 6 x rituximab + 6 x CHOP-21 n = 622 R 6 x rituximab + 4 x CHOP-21

42 Retrospective analysis of 365 patients treated with R-CHOP Med f-up: 33 months 10% of the patients: «very good risk» (IPI=0) 4-y PFS: 94% 4-y OS: 94% Sehn LH et al. Blood 2007;109:1857

Traitement des lymphomes diffus à grandes cellules B

Traitement des lymphomes diffus à grandes cellules B Traitement des lymphomes diffus à grandes cellules B Corinne HAIOUN Unité Hémopathies Lymphoïdes- CHU Henri Mondor Université Paris Est Créteil DES Hématologie Février 2012 On February 10th, the merging

More information

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%

More information

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective

More information

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

Radiotherapy in aggressive lymphomas. Umberto Ricardi

Radiotherapy in aggressive lymphomas. Umberto Ricardi Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive

More information

Head and Neck: DLBCL

Head and Neck: DLBCL Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels

Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell

More information

Rituximab in the Treatment of NHL:

Rituximab in the Treatment of NHL: New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,

More information

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and

More information

Lymphomas in Prof Paul Ruff Division of Medical Oncology

Lymphomas in Prof Paul Ruff Division of Medical Oncology Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:

More information

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and

More information

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc. The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation

More information

LYMPHOMA IN OLDER PEOPLE. Ama Rohatiner, St. Bartholomew s Hospital, Londonj

LYMPHOMA IN OLDER PEOPLE. Ama Rohatiner, St. Bartholomew s Hospital, Londonj LYMPHOMA IN OLDER PEOPLE Ama Rohatiner, St. Bartholomew s Hospital, Londonj LYMPHOMA IN OLDER PEOPLE PERSPECTIVES HALF OF ALL NEWLY-DIAGNOSED PTS. WITH LYMPHOMA ARE >60 MAY REQUIRE DIFFERENT MANAGEMENT

More information

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific

More information

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma 12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma

More information

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account

More information

Jonathan W Friedberg, MD, MMSc

Jonathan W Friedberg, MD, MMSc I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer

More information

Transformed lymphoma: biology and treatment

Transformed lymphoma: biology and treatment Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability

More information

New Targets and Treatments for Follicular Lymphoma

New Targets and Treatments for Follicular Lymphoma Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,

More information

Targeted Radioimmunotherapy for Lymphoma

Targeted Radioimmunotherapy for Lymphoma Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,

More information

SEQUENCING FOLLICULAR LYMPHOMA

SEQUENCING FOLLICULAR LYMPHOMA SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial

More information

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing

More information

Overview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC

Overview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC 2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly

More information

What are the hurdles to using cell of origin in classification to treat DLBCL?

What are the hurdles to using cell of origin in classification to treat DLBCL? What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

MANAGEMENT OF LYMPHOMAS

MANAGEMENT OF LYMPHOMAS MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association

More information

Managing patients with relapsed follicular lymphoma. Case

Managing patients with relapsed follicular lymphoma. Case Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell

More information

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy

More information

Overview of Lymphoma Clinical Trials

Overview of Lymphoma Clinical Trials Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants

More information

Patterns of Care in Medical Oncology. Follicular Lymphoma

Patterns of Care in Medical Oncology. Follicular Lymphoma Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy

More information

Mathias J Rummel, MD, PhD

Mathias J Rummel, MD, PhD I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track

More information

POST ICML Indolent lymphomas relapse treatment

POST ICML Indolent lymphomas relapse treatment POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line

More information

What is the best approach to the initial therapy of PTCL? standards of treatment? Should all

What is the best approach to the initial therapy of PTCL? standards of treatment? Should all What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital

More information

Angioimmunoblastic T-cell lymphoma: nobody knows what to do...

Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte

More information

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Treatment Nodal Marginal Zone Lymphoma

Treatment Nodal Marginal Zone Lymphoma Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment

More information

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

More information

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine

More information

Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma

Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Post-ESMO Berne

Post-ESMO Berne Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle

More information

Non-Hodgkin lymphoma

Non-Hodgkin lymphoma Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma

More information

First Line Management of Classical Hodgkin Lymphoma

First Line Management of Classical Hodgkin Lymphoma First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /

More information

PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be

PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is

More information

LYMPHOMA in HIV PATIENTS. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma

LYMPHOMA in HIV PATIENTS. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma LYMPHOMA in HIV PATIENTS Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma Lugano, 3-4 November 2017 Disclosures: Roche: honoraria Gilead: travel grant ESMO Preceptorship

More information

Aggressive B and T cell lymphomas: Treatment paradigms in 2018

Aggressive B and T cell lymphomas: Treatment paradigms in 2018 Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate

More information

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many

More information

Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes

Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie

More information

Lymphoma. André Bosly M.D.,Ph.D. Post ASH meeting 10/01/2014 Sheraton Brussels National Airport

Lymphoma. André Bosly M.D.,Ph.D. Post ASH meeting 10/01/2014 Sheraton Brussels National Airport Lymphoma André Bosly M.D.,Ph.D. Post ASH meeting 10/01/2014 Sheraton Brussels National Airport Lymphoma Hodgkin Lymphoma (HL) Indolent Lymphoma (inhl) Diffuse Large B Cell Lymphoma (DLBCL) Hodgkin Lymphoma

More information

Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA

Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead

More information

Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents

Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30

More information

Role of PET in staging and treatment of lymphomas

Role of PET in staging and treatment of lymphomas Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging

More information

R/R DLBCL Treatment Landscape

R/R DLBCL Treatment Landscape An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,

More information

Lymphoma- Med A-new drugs and treatments

Lymphoma- Med A-new drugs and treatments Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is

More information

CAR-T cell therapy pros and cons

CAR-T cell therapy pros and cons CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research

More information

ASCO abstract June 2007 :Othieno-Abinya NA, Abwao HO, Kiarie GW)

ASCO abstract June 2007 :Othieno-Abinya NA, Abwao HO, Kiarie GW) Inferior outcome of poor prognostic phenotype non- Hodgkin s lymphoma treatment among HIV positive patients compared with HIV negative counterparts in the HAART era. (ASCO abstract June 2007 :Othieno-Abinya

More information

How I treat High-risk follicular lymphoma

How I treat High-risk follicular lymphoma How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334

More information

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin

More information

Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives

More information

The case for maintenance rituximab in FL

The case for maintenance rituximab in FL New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P

More information

PET-imaging: when can it be used to direct lymphoma treatment?

PET-imaging: when can it be used to direct lymphoma treatment? PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict

More information

Sally Barrington Martin Hutchings

Sally Barrington Martin Hutchings Sally Barrington Martin Hutchings Therapeutic implications of BMI Bone marrow involvement means extranodal disease and by definition stage IV BMI detected by BMB is a poor prognostic feature in most lymphomas

More information

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng

More information

ASTRO Refresher Course Lymphoma. Chris Kelsey, M.D. Duke University Medical Center

ASTRO Refresher Course Lymphoma. Chris Kelsey, M.D. Duke University Medical Center ASTRO Refresher Course 2015 Lymphoma Chris Kelsey, M.D. Duke University Medical Center Disclosure Varian Medical Systems Research funding for lung cancer trial Learning Objectives Awareness of Deauville

More information

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide

More information

LYMPHOMA PROGNOSTIC INDEXES AND EMERGING NEW BIOMARKERS

LYMPHOMA PROGNOSTIC INDEXES AND EMERGING NEW BIOMARKERS Lyfe Forum of excellence 2016 What's new in Lymphoyd neoplasia? IOSI course, Bellinzona, 29-31 January 2016 LYMPHOMA PROGNOSTIC INDEXES AND EMERGING NEW BIOMARKERS DR. STEFANO LUMINARI ASSOCIATE PROFESSOR

More information

Role of PET in staging and treatment of lymphomas

Role of PET in staging and treatment of lymphomas Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging

More information

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar

More information

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Update on lymphoma management: Diffuse large B-Cell NHL

Update on lymphoma management: Diffuse large B-Cell NHL Hematology, 2005; 10 Supplement 1: 10 /14 NON-HODGKIN S LYMPHOMA Update on lymphoma management: Diffuse large B-Cell NHL JULIE M. VOSE, NEUMANN M. & MILDRED E. HARRIS Section of Hematology/Oncology, University

More information

Mantle Cell Lymphoma. A schizophrenic disease

Mantle Cell Lymphoma. A schizophrenic disease 23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving

More information

Updates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics

Updates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,

More information

How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma

How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del

More information

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful

More information

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital

More information

Options in Mantle Cell Lymphoma Therapy

Options in Mantle Cell Lymphoma Therapy Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of

More information

Brad S Kahl, MD. Tracks 1-21

Brad S Kahl, MD. Tracks 1-21 I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical

More information

Mantle cell lymphoma An update on management

Mantle cell lymphoma An update on management Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag

More information

News from EHA. Linfomi. Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma

News from EHA. Linfomi. Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma News from EHA Linfomi Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Outline HD advanced disease first line therapy : intensity of chemotherapy and PET guided

More information

Pros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen

Pros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen 3rd International Workshop on in Lymphoma Menton, September 26, 2011 Afternoon Controversies Pros and Cons: in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen Pros Is there any

More information

Nuove opportunità di cura. Stefano Sacchi, Modena

Nuove opportunità di cura. Stefano Sacchi, Modena Nuove opportunità di cura Stefano Sacchi, Modena Antiangiogenesis therapies The goal is to target the blood supply that feeds tumors. Vorinostat (suberoylanilide hydroxamic acid - SAHA) TOPIC SEARCH:

More information

KEYWORDS: Aggressive lymphoma, High-dose therapy, Autologous stem cell transplant, Immunochemotherapy INTRODUCTION

KEYWORDS: Aggressive lymphoma, High-dose therapy, Autologous stem cell transplant, Immunochemotherapy INTRODUCTION Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of a Phase II GOELAMS Study Marie-Sarah Dilhuydy, 1 Thierry

More information

Highlights of ICML 2015

Highlights of ICML 2015 Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465

More information

Emerging targeted therapies for follicular lymphoma A future without chemotherapy

Emerging targeted therapies for follicular lymphoma A future without chemotherapy Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS

More information

Il trattamento del Linfoma Follicolare in prima linea

Il trattamento del Linfoma Follicolare in prima linea Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6

More information

Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma

Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY

More information

Follicular Lymphoma 2016:

Follicular Lymphoma 2016: Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual

More information

Challenges in the Treatment of Follicular Lymphoma

Challenges in the Treatment of Follicular Lymphoma Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High

More information

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? Annals of Hematology (2018) 97:2129 2135 https://doi.org/10.1007/s00277-018-3437-z ORIGINAL ARTICLE Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

More information

Updates in T cell Lymphoma

Updates in T cell Lymphoma Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront

More information

Non-Hodgkin s Lymphoma

Non-Hodgkin s Lymphoma Non-Hodgkin s Lympoma Non-Hodgkin s Lymphomas Janet H. Van Cleave MSN, ACNP-CS, CS, AOCN Acute Care Nurse Practitioner The Mount Sinai Medical Center of New York City Doctoral Student, Yale University

More information

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies

More information

Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University

Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable

More information

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.

More information

NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12

NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12 NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References

More information